Subcutaneous Self Injection Markets to 2026


immunotherapeutic drugs devices patient enablement          Published November 2019 •  Catalog no. SSJ4X9  •  Price US $3,850


A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application. As these combination products have proliferated, so too have product strategies. Several pharma and biotech companies are embracing the combination product concept and using it to differentiate their drug offerings, while others are opting for a minimalist approach. Interferons for treating Multiple Sclerosis are primarily marketed in prefilled syringes, while human growth hormone indicated for hormone deficiency in children is supplied almost exclusively in reusable, custom-designed variable dose pen injectors. Even within a particular therapeutic drug class, strategic variations are evident.

Bar_Graph Subcutaneous Self-Injection Markets to 2026 Report Brochure (Download PDF)

Blue document  Subcutaneous Self Injection Markets to 2026 Report Order Form (Download PDF)



Subcutaneous Self Injection Markets to 2026 – What You Will Learn

• Provides detailed analysis of self-administered subcutaneous drug products, drug delivery and device strategies, and product development factors
• Assesses key markets, market dynamics and market demographics
• Analyzes therapeutic demand drivers and evaluates SC drug products in nine key therapeutic segments
• Provides market data and forecasts to 2026
• Profiles market sector participants, their product development activities, business strategies, and corporate alliances and affiliations
• Assesses the importance of alliances and partnerships on self-administered subcutaneous drug product commercialization
• Evaluates the impact of economic, technology, and regulatory factor

Subcutaneous Self Injection Markets to 2026 – Summary of Contents

Executive Summary
The Market Opportunity
Subcutaneous Self-Administration – Why it’s Growing
The Evolving Drug Pipeline
Device and Packaging Technology Advances
Shifting Patient Demographics
Healthcare Economics
Demand Drivers
Innovation in Prefilled Device Designs
Therapeutic Targets and Treatment
Competitive Landscape
Risk Factors
Subcutaneous Delivery Device Design Factors
Ergonomics and Ease of Use
Safety Features
Lyophilized Drugs/Reconstitution
High Viscosity Drugs
High Volume Drugs
Subcutaneously Delivered Drugs – Device Strategies
Handheld Devices
Prefilled Syringes
Pen Injectors
Dual Chamber Pens
Emerging Devices
Other Handheld Devices
Needle-free Injectors
Wearable Devices
Patch Pumps
Large Volume Wearable Devices
Subcutaneous Self-Administration
Therapeutic Sector Product Analysis & Forecasts
Autoimmune Diseases
Rheumatoid Arthritis
Psoriatic Arthritis
Juvenile Ideopathic Arthritis
Ankylosing Spondylitis
Crohn’s Disease
Autoimmune Anti-Inflammatory SC Therapeutics
Interleukin Receptor Agonists
TNF Inhibitors
Multiple Sclerosis
Type 2 Glycemic control
Hormone Replacement
Reproductive Health
Market Factors
Regulatory Issues
DTC Marketing
Market Sector Participant Profiles